论文部分内容阅读
临床试验用免疫球蛋白制品作为被动免疫措施其声誉不佳。但那都是在乙型肝炎还不能与其他类型肝炎鉴别、制品中的特异性抗—HBs 的含量还不能测定的时候所得到的结果。利用检测抗—HBs 的方法已有可能选择高效价血浆供制造乙型肝炎免疫球蛋白之用。许多研究用含低效价抗—HBs 的普通免疫球蛋白作为对照剂,但这种试验设计使得对结果的解释多少有些问题,因为普通免疫球蛋白对乙型肝炎的预防也可能有效。研究结果也提示普通免疫球蛋白可能有一定保护作用,但乙型肝炎免疫球蛋白的作用可能更大些。这两种免疫球蛋白预防肝炎的临床应用可归纳为:接触后预防;接触前或慢性接触时的
Clinical trials of immunoglobulin products as a passive immunization measure its reputation. But that was the result when hepatitis B could not be identified with other types of hepatitis and the level of specific anti-HBs in the product could not be determined. It has been possible to select high titer plasma for the manufacture of hepatitis B immunoglobulins using the method of detecting anti-HBs. Many studies used normal immunoglobulins with low titers of anti-HBs as controls, but this experimental design makes the interpretation of the results somewhat more problematic, since the prevention of hepatitis B by common immunoglobulins may also be effective. The results also suggest that ordinary immunoglobulin may have a protective effect, but the role of hepatitis B immunoglobulin may be greater. The clinical utility of these two immunoglobulins in the prevention of hepatitis can be summarized as: post-exposure prophylaxis; pre-exposure or chronic exposure